Skip to content

Roivant Sciences ROIV Deferred Revenue

Deferred Revenue at other companies

Moderna logo
ModernaMRNA
$102M-18.4%
Regenxbio logo
RegenxbioRGNX
$5.92M-56.4%
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$5.41M
Revvity logo
RevvityRVTY

Other financials

Income statement

See full
Revenue$2.5M-66.7%
Operating income-$339.2M-23.6%
Net income-$265.9M-257%
EPS (diluted)-$0.38-265%

Balance sheet

See full
Cash & equivalents$1.4B+1,411%
Total debt$107.4M+7.3%
Total equity$4.5B-3.4%
Total assets$5.7B+5.0%

Cash flow

See full
Operating cash flow-$163.8M+5.1%
CapEx$1.3M+55.5%
Free cash flow-$165.1M+4.8%

Valuation

See full
Market cap$25.25B+226%
Enterprise value$23.93B+209%
P/S3,056.5×+2,723×

Profitability

See full
Operating margin-9,130.5%-13,995pp
Net margin-6,079.9%-6,193pp
FCF margin-9,183.5%-17,093pp

Returns & leverage

See full
Return on equity-17.1%-17.7pp
Debt / equity0.0×
Current ratio18.4×-15.1×

Where this comes from

Reported directly by Roivant Sciences in its filing.

Tagged under the XBRL concept us-gaap:DeferredRevenueCurrent.

The official record: Roivant Sciences’s 10-Q, filed February 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Roivant Sciences's deferred revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Roivant Sciences's deferred revenue?
Roivant Sciences (ROIV) reported deferred revenue of $3.05M in Q4 2025.
How has Roivant Sciences's deferred revenue changed year-over-year?
Roivant Sciences's deferred revenue increased by 0.4% year-over-year, from $3.04M to $3.05M.
What does deferred revenue mean?
Payments received from customers for goods or services to be delivered within one year — recognized as revenue as performance obligations are satisfied.